drugset / Trial / NCT00982878
The Maraviroc Central Nervous System (CNS) Study
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to describe the Central Nervous System exposure of maraviroc in HIV-1 infected subjects receiving a stable antiretroviral regimen, including maraviroc, at steady state.
Timeline
- Start
- 2009-09
- Primary completion
- 2010-07
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maraviroc | Other / unclassified | 150 mg | — |